Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Zimmer Biomet Holdings, Inc. or Stevanato Group S.p.A. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A. compare based on key financial metrics to determine which better meets your investment needs.

About Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Latest Health Care Equipment & Supplies and Zimmer Biomet Holdings, Inc., Stevanato Group S.p.A. Stock News

As of September 2, 2026, Zimmer Biomet Holdings, Inc. had a $19.0 billion market capitalization, compared to the Health Care Equipment & Supplies median of $416.1 million. Zimmer Biomet Holdings, Inc.’s stock is up 11.4% in 2026, up 0.7% in the previous five trading days and down 5.25% in the past year.

Currently, Zimmer Biomet Holdings, Inc.’s price-earnings ratio is 24.2. Zimmer Biomet Holdings, Inc.’s trailing 12-month revenue is $8.5 billion with a 9.5% net profit margin. Year-over-year quarterly sales growth most recently was 4.8%. Analysts expect adjusted earnings to reach $8.534 per share for the current fiscal year. Zimmer Biomet Holdings, Inc. currently has a 1.0% dividend yield.

As of September 2, 2026, Stevanato Group S.p.A. had a $5.7 billion market cap, putting it in the 69th percentile of all stocks. Stevanato Group S.p.A.’s stock is up 3.3% in 2026, down 6.8% in the previous five trading days and down 8.48% in the past year.

Currently, Stevanato Group S.p.A.’s price-earnings ratio is 37.0. Stevanato Group S.p.A.’s trailing 12-month revenue is $1.4 billion with a 11.0% net profit margin. Year-over-year quarterly sales growth most recently was 4.9%. Analysts expect adjusted earnings to reach $0.704 per share for the current fiscal year. Stevanato Group S.p.A. currently has a 0.3% dividend yield.

How We Compare Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A. Stock Value Grades

Company	Ticker	Value
Zimmer Biomet Holdings, Inc.	ZBH	C
Stevanato Group S.p.A.	STVN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Zimmer Biomet Holdings, Inc. has a Value Score of 55, which is Average. Stevanato Group S.p.A. has a Value Score of 25, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Zimmer Biomet Holdings, Inc. or Stevanato Group S.p.A. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Zimmer Biomet Holdings, Inc. or Stevanato Group S.p.A. is the better investment when it comes to value.

Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A.’s Quality Grades

Company	Ticker	Quality
Zimmer Biomet Holdings, Inc.	ZBH	A
Stevanato Group S.p.A.	STVN	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Zimmer Biomet Holdings, Inc. has a Quality Score of 88, which is Very Strong. Stevanato Group S.p.A. has a Quality Score of 75, which is Strong.

The Quality Grade Winner: Zimmer Biomet Holdings, Inc.

As you can clearly see from the Quality Grade breakdown above, Zimmer Biomet Holdings, Inc. has a better overall quality grade than Stevanato Group S.p.A.. For investors who are looking for companies with higher quality than others in the same industry, Zimmer Biomet Holdings, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Zimmer Biomet Holdings, Inc.	ZBH	B
Stevanato Group S.p.A.	STVN	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Zimmer Biomet Holdings, Inc. has a Earnings Estimate Score of 71, which is Positive. Stevanato Group S.p.A. has a Earnings Estimate Score of 53, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Zimmer Biomet Holdings, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Zimmer Biomet Holdings, Inc. has a better Earnings Estimate Revisions Grade than Stevanato Group S.p.A.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Zimmer Biomet Holdings, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A. Grades

In addition to Quality, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Zimmer Biomet Holdings, Inc. or Stevanato Group S.p.A. Stock?

Overall, Zimmer Biomet Holdings, Inc. stock has a Value Score of 55, Estimate Revisions Score of 71 and Quality Score of 88.

Stevanato Group S.p.A. stock has a Value Score of 25, Estimate Revisions Score of 53 and Quality Score of 75.

Comparing Zimmer Biomet Holdings, Inc. and Stevanato Group S.p.A.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.